Navigation Links
Poniard Pharmaceuticals Announces Positive Tumor Response and Neuropathy Data from Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
Date:1/14/2009

partial response, as did 76 percent of patients in the FOLFOX arm, including seven patients with a partial response.

"These interim, proof-of-concept Phase 2 results are very encouraging and continue to suggest the potential of picoplatin as a neuropathy-sparing first-line therapy for metastatic colorectal cancer," said Robert De Jager, M.D., chief medical officer of Poniard. "We continue to observe the study participants to obtain progression-free and overall survival data. We expect that those data will support our primary goal of developing picoplatin as a preferred platinum therapy for patients with metastatic colorectal cancer who cannot tolerate the toxicity profile of currently marketed platinums."

About Picoplatin

Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tumors. It has an improved safety profile relative to existing platinum-based cancer therapies. Picoplatin has been evaluated in more than 750 patients and has demonstrated anti-tumor activity in multiple indications with less severe kidney toxicity (nephrotoxicity) and nerve toxicity (neurotoxicity) than is commonly observed with other platinum chemotherapy drugs. It is being studied in multiple cancer indications, treatment combinations and in two formulations.

In addition to the Phase 2 clinical trial in CRC, Poniard is evaluating intravenous picoplatin in an ongoing pivotal Phase 3 trial, known as SPEAR (Study of Picoplatin Efficacy After Relapse), in small cell lung cancer. This registration trial currently is being conducted under a Special Protocol Assessment (SPA) from the U.S. Food and Drug Administration and is evaluating overall survival as the primary endpoint. Picoplatin is also being evaluated in an ongoing Phase 2 clinical trial in patients with metastatic hormone-refractory prostate cancer. Oral picoplatin is being evaluated in a Phase 1 clinical trial in solid tumors. The
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Poniard Pharmaceuticals to Present Data from Phase 2 Clinical Trials of Picoplatin in Colorectal and Prostate Cancers
2. Poniard Pharmaceuticals Announces Commercial Supply Agreement for Picoplatin
3. Poniard Pharmaceuticals to Host Third Quarter 2008 Financial Results Conference Call on October 30
4. Poniard Announces Positive Incremental Efficacy and Safety Data from Phase 2 Picoplatin Trial in Patients With Metastatic Colorectal Cancer
5. Poniard Announces Positive Incremental Efficacy and Safety Data From Ongoing Phase 2 Picoplatin Trial in Hormone-Refractory Prostate Cancer
6. Poniard Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
7. Poniard Pharmaceuticals Announces Upcoming Conference Participation
8. Poniard Pharmaceuticals to Present at the 4th Annual Moores UCSD Cancer Center Translational Oncology Symposium
9. Poniard Pharmaceuticals Announces Upcoming Conference Participation
10. Poniard Pharmaceuticals to Host Second Quarter 2008 Financial Results Conference Call on July 31
11. Poniard Pharmaceuticals Appoints Four New Members to Clinical Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... PA (PRWEB) August 29, 2014 Pittcon ... Hub MacDonald, and colleague Koichiro Matsuda, Horiba Scientific, have ... on September 5, 2014. JASIS , Asia’s largest ... 3-5, 2014, in Makuhari Messe, Japan. , The ... Tools for Bioanalysis from Single Molecules to Single Cells” ...
(Date:8/29/2014)... 2014 Local veterinarian, Dr. Keith Clement, ... seeking candidates to participate in an investigational study of ... ultimate goal of this study is to determine if ... or two arthritically affected joints can help reduce pain ... for the current investigational study must be older than ...
(Date:8/29/2014)... Due to a misstatement posted by the ... Stem Cell Technology Center, LLC ( ASCTC ) was reported ... research that might benefit ALS patients. Because of ASCTC's ... cell technologies and therapeutic applications, FRC listed ASCTC as one ... donors who wish not to support research that requires the ...
(Date:8/29/2014)... San Antonio, TX (PRWEB) August 29, 2014 ... 9001:2008 and ISO 13485:2003 certified, GAMP® 5 compliant ... been awarded an international Phase II clinical trial ... non-Hodgkin’s lymphoma. , Throughout this trial, Intrinsic Imaging ... but not limited to, protocol and charter development, ...
Breaking Biology Technology:Fifth Annual U.S. Symposium at JASIS Organized by Pittcon’s Program Chairman Hub MacDonald 2Burnt Hills Veterinary Hospital Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 2The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 3Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2
... on November 2nd and New York on November ... Inc. (Nasdaq:,FVRL), a biopharmaceutical company developing patient-specific, active,immunotherapies ... the,Company will present at three upcoming investor conferences: ... Ghalie, M.D., Chief Medical Officer, will present at ...
... (Nasdaq:,SIAL), a life science company dedicated to providing ... and Oxford,BioMedica (LSE: OXB), a leading gene therapy ... confirming the strength and validity of,intellectual property owned ... field to Sigma-Aldrich. The ruling was part of ...
... to "de-cloak" cancers -, TORONTO, Oct. 25 ... company discovering and developing the next wave of,antibody ... from its Trop-2 and CD59 antibody programs. ARIUS ... at the AACR press,conference today at 9:30 a.m. ...
Cached Biology Technology:Favrille to Present at BIOCOM Investor Conference, Acumen BioFin Rodman & Renshaw Healthcare Conference and CIBC World Markets Healthcare Conference 2Sigma-Aldrich and Oxford BioMedica Win Key Ruling in Open Biosystems Patent Infringement Dispute 2Sigma-Aldrich and Oxford BioMedica Win Key Ruling in Open Biosystems Patent Infringement Dispute 3Arius announces new findings in Trop-2 and CD59 CANCER antibody programs 2Arius announces new findings in Trop-2 and CD59 CANCER antibody programs 3
(Date:9/1/2014)... nucleotidethe basic building block of DNAcould initiate fragile X syndrome, the ... The Journal of Cell Biology . ... gene on the X chromosome called fragile X mental retardation ... 360 men carry a so-called premutation, in which a series of ... is slightly longer than normal. These repeats are prone to even ...
(Date:9/1/2014)... As nocturnal animals, bats are perfectly adapted to a life ... between the reflected echoes to measure distance to obstacles or ... different echo delays. A study carried out by researchers at ... that this map dynamically adapts to external factors. , ... bat flies in too close to an object, the number ...
(Date:8/31/2014)... Scientists at the University of Warwick have discovered that ... , The substance, methylglyoxal - MG, was found ... of bad cholesterol from the body. , Low ... to heart disease, with increased levels of MG being ... kidney problems. , Supported by funding from the ...
Breaking Biology News(10 mins):A nucleotide change could initiate fragile X syndrome 2Zooming in for a safe flight 2Sugar substance 'kills' good HDL cholesterol, new research finds 2
... carried through the atmosphere before settling on the ocean ... new research from the University of Michigan and the ... Earth Science and Technology (SOEST) combines biogeochemistry and direct ... cycle is colliding with ocean fishand the human seafood ...
... members from The University of Texas at Arlington are ... of Texas System Board of Regents for excellence in ... $25,000 cash award and recognize faculty members at UT ... innovation at the undergraduate level. The professors were recognized ...
... Center Researcher Song-Yi Park, PhD, along with her colleagues, ... vegetables may lower the risk of invasive bladder cancer ... part of the Multiethnic Cohort (MEC) Study, established in ... factors, and cancer risk. Park and her fellow researcher,s ...
Cached Biology News:Ocean fish acquire more mercury at depth 2Ocean fish acquire more mercury at depth 3Ocean fish acquire more mercury at depth 49 UT Arlington educators honored for teaching excellence 2
IC50: 3 ng/ml · Limit of detection: 0.9 ng/ml...
Request Info...
Request Info...
... siRNA service provides the premium quality siRNAs ... Custom siRNAs can be readily ordered online ... sequence, or by providing the sense and ... Silencer Validated and Silencer Pre-designed siRNAs, which ...
Biology Products: